Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc. (NASDAQ: POZN), today announced results for the third quarter ended September 30, 2009.

Third Quarter Results

POZEN reported a net income of $6.7 million, or $0.22 per share on a diluted basis, for the third quarter of 2009, compared to net loss of $(7.9) million, or $(0.26) per share on a diluted basis, for the third quarter of 2008.

For the third quarter of 2009, POZEN reported revenue of $14.3 million resulting from a $10 million milestone payment for the New Drug Application (NDA) filing for VIMOVO™ (naproxen/esomeprazole magnesium), the amortization of upfront payments received pursuant to the collaboration agreement with AstraZeneca of $3.1 million and royalties of $1.2 million on sales of Treximet® (sumatriptan and naproxen sodium). Revenue for the third quarter ended September 30, 2008 totaled $11.1 million, resulting from the amortization of upfront payments received pursuant to the collaboration agreements with AstraZeneca and GlaxoSmithKline of $3.2 million, $7.5 million of revenue for development work, and $0.4 million of royalties on sales of Treximet.

Operating expenses for the third quarter of 2009 totaled $7.7 million as compared to $19.5 million for the comparable period in 2008. The decrease in operating expenses was primarily due to a decrease in costs associated with the PN 400 development program.

At September 30, 2009, cash, cash equivalents and short-term investments totaled $51.3 million compared to $61.7 million at December 31, 2008. The Company continues to anticipate ending the year with greater than $45.0 million in cash and investments.

Nine-Month Results

POZEN reported a net loss of $(1.1) million, or $(0.04) per share on a diluted basis, for the nine month period ended September 30, 2009, compared to a net loss of $(1.9) million, or $(0.06) per share on a diluted basis, for the same period in 2008.

For the nine months ended September 30, 2009, POZEN reported revenue of $28.0 million compared to $52.1 million for the same period in 2008. The decrease in revenue was primarily due to $14.6 million less development revenue in 2009 and $10.0 million less in milestone payments in 2009.

Operating expenses for the nine months ended September 30, 2009 were $29.5 million as compared to $55.7 million for the same period in 2008. The decrease in operating expenses was primarily due to a decrease in costs for the PN 400 development program.

Source POZEN

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.